The mechanism and advantages of Vigabatrin (vigabatrin) in the treatment of epilepsy

Vigabatrin (Vigabatrin) is an anti-epileptic drug used to treat epilepsy, especially in patients with refractory epilepsy. Its main mechanism of action is to irreversibly inhibit γ-aminobutyric acid transaminase (GABA-T) in the brain, thereby increasing the concentration of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) in the brain. GABAAs the main inhibitory neurotransmitter in the central nervous system, it can reduce the excitability of neurons and help control epileptic seizures.

Vigabatrin can effectively stabilize the excitability of neuronal membranes and reduce the occurrence of abnormal electrical activity by enhancing the inhibitory effect ofGABA. This mechanism of action makes it effective in the treatment of complex partial epilepsy and infantile spasticity. Compared with other anti-epileptic drugs, Vigabatrin has more obvious therapeutic advantages in specific types of epilepsy, especially in patients who have poor response to traditional drugs, showing unique efficacy.

In addition, Vigabatrin works quickly during treatment and can quickly reduce the frequency and intensity of epileptic seizures. It is convenient for oral administration and has good patient compliance. Vigabatrin is also widely used in children and infants, especially in the treatment of Spanish spasticity, which has achieved remarkable results and improved the quality of life and prognosis of children.

Finally, the safety of Vigabatrin is relatively clear, but it should be noted that long-term use may cause side effects such as visual field defects, so visual function needs to be monitored regularly during treatment. In general, Vigabatrin increases GABA levels through a unique mechanism and shows good efficacy and advantages for specific types of epilepsy, making it an important treatment option for patients with refractory epilepsy.

Reference materials:https://www.sabril.net/